Erasca, Inc. (ERAS) saw its stock price soar 5.12% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.
The surge appears to be driven by a series of positive analyst actions reported pre-market. Mizuho raised its price target on Erasca to $19 from $16 while maintaining an Outperform rating. Separately, H.C. Wainwright & Co. maintained its Buy rating on the stock and significantly increased its price target to $20 from $15. These bullish stances from analysts likely provided the catalyst for the stock's strong performance at the market open.